CA2237052A1 - Substituted diaminocarboxylic acids - Google Patents

Substituted diaminocarboxylic acids Download PDF

Info

Publication number
CA2237052A1
CA2237052A1 CA002237052A CA2237052A CA2237052A1 CA 2237052 A1 CA2237052 A1 CA 2237052A1 CA 002237052 A CA002237052 A CA 002237052A CA 2237052 A CA2237052 A CA 2237052A CA 2237052 A1 CA2237052 A1 CA 2237052A1
Authority
CA
Canada
Prior art keywords
formula
compound
phenyl
alkyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002237052A
Other languages
English (en)
French (fr)
Inventor
Werner Thorwart
Wilfried Schwab
Manfred Schudok
Burkhard Haase
Bernhard Neises
Gunter Billen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19719585A external-priority patent/DE19719585A1/de
Priority claimed from DE19719428A external-priority patent/DE19719428A1/de
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of CA2237052A1 publication Critical patent/CA2237052A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002237052A 1997-05-09 1998-05-07 Substituted diaminocarboxylic acids Abandoned CA2237052A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19719585A DE19719585A1 (de) 1997-05-09 1997-05-09 Substituierte Diaminocarbonsäuren
DE19719585.7 1997-05-09
DE19719428.1 1997-05-12
DE19719428A DE19719428A1 (de) 1997-05-12 1997-05-12 Substituierte Diaminocarbonsäuren

Publications (1)

Publication Number Publication Date
CA2237052A1 true CA2237052A1 (en) 1998-11-09

Family

ID=26036417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002237052A Abandoned CA2237052A1 (en) 1997-05-09 1998-05-07 Substituted diaminocarboxylic acids

Country Status (18)

Country Link
US (2) US6159995A (enExample)
EP (1) EP0877019B1 (enExample)
JP (1) JP4177484B2 (enExample)
KR (1) KR19980086893A (enExample)
AR (1) AR012675A1 (enExample)
AT (1) ATE210639T1 (enExample)
AU (1) AU736700B2 (enExample)
BR (1) BR9801604A (enExample)
CA (1) CA2237052A1 (enExample)
CZ (1) CZ143998A3 (enExample)
DE (1) DE59802394D1 (enExample)
DK (1) DK0877019T3 (enExample)
ES (1) ES2165640T3 (enExample)
HU (1) HUP9801045A3 (enExample)
ID (1) ID20809A (enExample)
PL (1) PL326218A1 (enExample)
PT (1) PT877019E (enExample)
TR (1) TR199800818A3 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277987B1 (en) 1998-02-04 2001-08-21 Novartis Ag Sulfonylamino acid and sulfonylamino hydroxamic acid derivatives
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
CN1304402A (zh) * 1998-04-03 2001-07-18 三共株式会社 磺酰胺衍生物
ATE227295T1 (de) 1998-07-16 2002-11-15 Aventis Pharma Gmbh Phosphin- und phosphonsäurederivate als arzneimittel
EP1165530A2 (en) 1999-03-03 2002-01-02 The Procter & Gamble Company Dihetero-substituted metalloprotease inhibitors
IL145089A0 (en) * 1999-03-03 2002-06-30 Procter & Gamble Alkenyl-and alkynyl-containing metalloprotease inhibitors
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
US6506786B2 (en) * 2001-02-13 2003-01-14 Pharmacor Inc. HIV protease inhibitors based on amino acid derivatives
US20040235896A1 (en) * 2001-03-14 2004-11-25 Fujimoto Roger Aki Certain azacycloalkyl substituted acetic acid derivatives
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0103710D0 (sv) * 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
US7388008B2 (en) * 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
ES2539527T3 (es) * 2005-04-27 2015-07-01 Taimed Biologics, Inc. Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas
JP2009517412A (ja) * 2005-11-30 2009-04-30 アンブリリア バイオファーマ インコーポレイテッド アスパルチルプロテアーゼ阻害物質のリジンベースのプロドラッグ及びその調製方法
US8410300B2 (en) 2006-09-21 2013-04-02 Taimed Biologics, Inc. Protease inhibitors
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
US8093265B2 (en) 2007-03-09 2012-01-10 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
CA2970578C (en) 2014-12-17 2024-01-02 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and n-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
EP3560917B1 (en) * 2016-12-22 2023-12-20 Guangzhou Chinaray Optoelectronic Materials Ltd. Polymer containing furan crosslinking group and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2764262B2 (ja) * 1987-08-28 1998-06-11 持田製薬株式会社 ヒダントイン誘導体及びそれを有効成分とする医薬組成物
TW201303B (enExample) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US6022898A (en) * 1994-06-22 2000-02-08 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) * 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
US5977141A (en) * 1995-11-17 1999-11-02 Warner-Lambert Company Sulfonamide inhibitors of matrix metalloproteinases
WO1997045402A1 (fr) 1996-05-24 1997-12-04 Ono Pharmaceutical Co., Ltd. Derives de phenylsulfonamide

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277987B1 (en) 1998-02-04 2001-08-21 Novartis Ag Sulfonylamino acid and sulfonylamino hydroxamic acid derivatives
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases

Also Published As

Publication number Publication date
AU6482498A (en) 1998-11-12
AU736700B2 (en) 2001-08-02
TR199800818A2 (xx) 1998-11-23
TR199800818A3 (tr) 1998-11-23
PT877019E (pt) 2002-05-31
ES2165640T3 (es) 2002-03-16
KR19980086893A (ko) 1998-12-05
HUP9801045A2 (hu) 1999-06-28
EP0877019B1 (de) 2001-12-12
DE59802394D1 (de) 2002-01-24
EP0877019A1 (de) 1998-11-11
ATE210639T1 (de) 2001-12-15
PL326218A1 (en) 1998-11-23
AR012675A1 (es) 2000-11-08
BR9801604A (pt) 1999-06-08
JPH11228529A (ja) 1999-08-24
DK0877019T3 (da) 2002-04-08
HU9801045D0 (en) 1998-07-28
US6355673B1 (en) 2002-03-12
US6159995A (en) 2000-12-12
ID20809A (id) 1999-03-11
JP4177484B2 (ja) 2008-11-05
CZ143998A3 (cs) 1998-11-11
HUP9801045A3 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
CA2237052A1 (en) Substituted diaminocarboxylic acids
AU732723B2 (en) Sulfonylaminocarboxylic acids
CA2237590C (en) Cyclic and heterocyclic n-substituted .alpha.-iminohydroxamic and -carboxylic acids
EP0950656B1 (en) Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
US5962640A (en) Methods for preparing novel dipeptide compounds or pharmacuetically acceptable salts thereof
AU2013324696A1 (en) Alpha hydroxy amides
JP4384277B2 (ja) 置換された６−および７−アミノテトラヒドロイソキノリンカルボン酸
US6335333B1 (en) N-arylsulfonylamino acid omega-amides
AU2001278188B2 (en) Tyrosine derivatives as phosphatase inhibitors
US6727266B2 (en) Substituted tryptophan derivatives
WO2000001383A1 (en) Angiogenesis inhibitors
Bui et al. Synthesis of sulfonylurea derivatives and their α-glucosidase inhibitory activity
RU2196768C2 (ru) Замещенные диаминокарбоновые кислоты
MXPA98003660A (en) Acidos diaminocarboxilicos sustitui
KR100820039B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 알킬아미노나프탈렌일옥시메틸 프로페닐 하이드록시벤즈아마이드유도체, 이의 제조방법 및 이를 유효성분으로 하는항암제용 약학 조성물
MXPA98003661A (en) Acids sulfonilaminocarboxili
EP1448180A1 (en) Para-amino benzoic acids as integrin antagonists
ITTO20090648A1 (it) Inibitori di adam17 atti a modulare il rilascio di alcam (cd166) solubile in cellule tumorali e loro uso nel trattamento terapeutico del carcinoma ovarico epiteliale (eoc)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued